| Fluvoxamine appears to have potential as a safe, inexpensive, and widely available medication that could be effectively repurposed to ameliorate serious COVID-19-related morbidity and mortality. |
| Fluvoxamine prevented clinical deterioration and long-lasting symptoms related to COVID-19 in initial studies and one large clinical trial, with several large clinical trials underway globally. |
| Current information may warrant clinician discussion of fluvoxamine as a treatment option for COVID-19, using shared decision making. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.